Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

Journal of Clinical Oncology

Volumn 27, Issue 27, 2009, Pages 4462-4468

  Rini, Brian I ^a   Wilding, George ^a   Hudes, Gary ^a   Stadler, Walter M ^a   Kim, Sinil ^a   Tarazi, Jamal ^a   Rosbrook, Brad ^a   Trask, Peter C ^a   Wood, Laura ^a   Dutcher, Janice P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; CYTOKINE; CYTOTOXIC AGENT; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LEUKOPENIA; LIMB PAIN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES;

EID: 70349388719     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.7034     Document Type: Article

References (28)

1. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Kidney cancer, v. 1, 2009. http://www.nccn.org/professionals/ physician-gls/PDF/kidney.pdf
2. Ljungberg B, Hanbury DC, Kuczyk MA, et al: Guidelines on renal cell carcinoma, 2007. http://www.uroweb.org/fileadmin/user-upload/Guidelines/08- Renal-Cell-Carcinoma-2007.pdf
3. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006
4. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006
5. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115-124, 2007
6. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 356:125-134, 2007
7. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006
8. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007
9. Rini BI, Halabi S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422-5428, 2008
10. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med 356:2271-2281, 2007
11. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
12. Eichelberg C, Heuer R, Chun FK, et al: Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: A retrospective outcome analysis. Eur Urol 54:1373-1378, 2008
13. Dudek AZ, Zolnierek J, Dham A, et al: Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115:61-67, 2009
14. Sablin MP, Bouaita L, Balleyguier C, et al: Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 25:244s, 2007 (suppl; abstr 5038)
15. Hu-Lowe DD, Zou HY, Grazzini ML, et al: Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272-7283, 2008
16. Rixe O, Bukowski RM, Michaelson MD, et al: Axitinib treatment in patients with cytokinerefractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 8:975-984, 2007
17. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
18. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. Cella D, Yount S, Du H, et al: Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 4:191-199, 2006
21. Cella D, Yount S, Brucker PS, et al: Development and validation of a scale to measure diseaserelated symptoms of kidney cancer. Value Health 10:285-293, 2007
22. Rini BI, Michaelson MD, Rosenberg JE, et al: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26:3743-3748, 2008
23. Escudier B, Ravaud A, Oudard S, et al: Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann Oncol 19:viii45, 2008 (suppl; abstr 720)
24. Rugo HS, Herbst RS, Liu G, et al: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483, 2005
25. Sakamoto KM: Su-11248 Sugen. Curr Opin Investig Drugs 5:1329-1339, 2004
26. Rixe O, Dutcher JP, Motzer RJ, et al: Association between diastolic blood pressure (DBP) G) ≥ 90 mm Hg and efficacy in patients with metastatic renal cell carcinoma receiving axitinib (AG-013736). Ann Oncol 19:viii189, 2008 (suppl 8; abstr 587PD)
27. Dutcher J, Rixe O, Motzer RJ, et al: Levothyroxine treatment of hypothyroidism and axitinib (AG-013736) efficacy in patients with metastatic renal cell carcinoma. 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, September 12, 2008-September 16, 2008
28. Bukowski R, Cella D, Gondek K, et al: Effects of sorafenib on symptoms and quality of life: Results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30:220-227, 2007